Conatus (CNAT), Galmed (GLMD), Intercept (ICPT) Could Be Given Similar Considerations for their Assets - FBR
- Wall Street dips as telecoms slump; AmEx surges
- Microsoft (MSFT) Tops Q1 EPS by 8c
- AMD (AMD) Posts Q3 Operating EPS of 3c; Sees Q4 Revenue Down Sequentially
- AT&T (T) Said to Discuss Idea of Takeover in Time Warner (TWX) Meetings
- Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
FBR Capital analyst Vernon Bernardino weighed in on the NASH space after Allergan (NASDAQ: AGN) agreed to acquire Tobira Therapeutics (NASDAQ: TBRA) for a 500% up-front payment and up to $49.84 per share in Contingent Value Rights (CVRs)
Bernardino commented, "While the acquisition premium (500% premium over yesterday's closing price of $4.74/share for TBRA) is outsized even in biotech terms, we think the drug development landscape in NASH, which has been estimated to have $40 billion in market potential, has no approved drugs and is comprised of less than a half dozen drug candidates in the Phase II stage of development. We think companies under our coverage that could be given similar consideration include Conatus Pharmaceuticals (NASDAQ: CNAT), and Galmed Pharmaceuticals (NASDAQ: GLMD), as well as Intercept Pharmaceuticals (NASDAQ: ICPT), which along with Genfit , are the only ones in the Phase III stage of development."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crown Castle (CCI) Misses Q3 AFFO by 2c, Revenues Beats
- Equity Bancshares (EQBK) Clears Final Regulatory Hurdle Needed to Close Community First Bancshares Merger; Moves to Acquire Prairie State Bancshares
- UPDATE: Qualcomm (QCOM), NXP Semiconductors (NXPI) Deal Could be Announced Next Week - Bloomberg
Create E-mail Alert Related CategoriesAnalyst Comments, Rumors
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!